Perspective [CATX] vs Axogen [AXGN] Detailed Stock Comparison

Perspective Therapeutics Inc.

NYSE
Loading...

Axogen Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: Perspective Therapeutics Inc. wins in 5 metrics, Axogen Inc. wins in 13 metrics, with 0 ties. Axogen Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Perspective Therapeutics Inc. Axogen Inc. Better
P/E Ratio (TTM) -3.22 -110.18 Perspective Therapeutics Inc.
Price-to-Book Ratio 1.62 13.15 Perspective Therapeutics Inc.
Debt-to-Equity Ratio 1.57 55.50 Perspective Therapeutics Inc.
PEG Ratio -3.84 0.04 Axogen Inc.
EV/EBITDA -3.38 -2,165.44 Perspective Therapeutics Inc.
Profit Margin (TTM) 0.00% -6.97% Perspective Therapeutics Inc.
Operating Margin (TTM) -92,632.56% -16.31% Axogen Inc.
Return on Equity -41.65% -13.49% Axogen Inc.
Return on Assets (TTM) -23.35% -2.31% Axogen Inc.
Free Cash Flow (TTM) $-95.23M $-4.78M Axogen Inc.
1-Year Return 53.31% 262.53% Axogen Inc.
Price-to-Sales Ratio (TTM) 581.70 8.27 Axogen Inc.
Enterprise Value $372.36M $1.89B Axogen Inc.
EV/Revenue Ratio 421.22 8.40 Axogen Inc.
Gross Profit Margin (TTM) N/A 74.13% N/A
Revenue per Share (TTM) $0 $5 Axogen Inc.
Earnings per Share (Diluted) $-1.41 $-0.34 Axogen Inc.
Beta (Stock Volatility) 1.87 0.98 Axogen Inc.
Short % of Float 14.32% 6.92% Axogen Inc.

Perspective Therapeutics Inc. vs Axogen Inc. Stock Performance Analysis

Loading Price Chart...

CATX
AXGN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Perspective Therapeutics Inc.-1.81%-13.46%-9.55%-32.71%75.61%29.03%
Axogen Inc.2.91%-4.80%-7.44%28.74%42.51%27.29%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Perspective Therapeutics Inc.53.31%-28.36%-55.73%-54.19%-62.48%-91.24%
Axogen Inc.262.53%346.61%108.01%590.21%1,114.77%9,770.00%

Performance & Financial Health Analysis: Perspective Therapeutics Inc. vs Axogen Inc.

MetricCATXAXGN
Market Information
Market Cap i$514.22M$1.94B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i1,385,8601,245,238
90 Day Avg. Volume i1,439,6771,068,353
Last Close$3.54$40.61
52 Week Range$1.96 - $6.16$9.22 - $45.83
% from 52W High-42.61%-11.39%
All-Time High$85.00 (Dec 12, 2005)$56.85 (Jul 23, 2018)
% from All-Time High-95.84%-28.57%
Growth Metrics
Quarterly Revenue GrowthN/A0.21%
Quarterly Earnings GrowthN/A0.21%
Financial Health
Profit Margin (TTM) i0.00%-0.07%
Operating Margin (TTM) i-926.33%-0.16%
Return on Equity (TTM) i-0.42%-0.13%
Debt to Equity (MRQ) i1.5755.50
Cash & Liquidity
Book Value per Share (MRQ)$2.79$2.73
Cash per Share (MRQ)$1.27$0.80
Operating Cash Flow (TTM) i$-82,484,000$812,000
Levered Free Cash Flow (TTM) i$-60,373,500$3.58M
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/A$0.00

Valuation & Enterprise Metrics Analysis: Perspective Therapeutics Inc. vs Axogen Inc.

MetricCATX (Apr 26, 2026)AXGN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i-3.22-110.18
Forward P/E i-3.8447.31
PEG Ratio i-3.840.04
Price to Sales (TTM) i581.708.27
Price to Book (MRQ) i1.6213.15
Market Capitalization
Market Capitalization i$514.22M$1.94B
Enterprise Value i$372.36M$1.89B
Enterprise Value Metrics
Enterprise to Revenue i421.228.40
Enterprise to EBITDA i-3.38-2,165.44
Risk & Other Metrics
Beta i1.870.98
Book Value per Share (MRQ) i$2.79$2.73

Financial Statements Comparison: Perspective Therapeutics Inc. vs Axogen Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricCATX (2025)AXGN (2025)
Revenue/Sales i0225.21M
Cost of Goods Sold iN/A57.86M
COGS % of Revenue i-25.7%
Gross Profit iN/A167.35M
Gross Margin i-74.3%
Research & Development i84.22M32.89M
Operating Income (EBIT) i-113.56M-7.85M
Operating Margin i--3.5%
EBITDA i-100.80M826,000
EBITDA Margin i-0.4%
Pre-Tax Income i-104.43M-15.70M
Pre-Tax Income % of Revenue i--7.0%
Income Tax i-793,000N/A
Income Tax % of Revenue i-0.0%
Net Income (Profit) i-103.12M-15.70M
Profit Margin i--7.0%

Balance Sheet & Liquidity Metrics

MetricCATX (2025)AXGN (2025)
Cash & Equivalents i30.63M35.55M
Total Current Assets i148.39M120.42M
Total Current Assets % of Revenue i-53.5%
Total Current Liabilities i28.68M23.56M
Total Current Liabilities % of Revenue i-10.5%
Long-Term Debt i2.57M65.26M
Long-Term Debt % of Revenue i-29.0%
Total Shareholders Equity i207.03M128.85M
Retained Earnings i-334.84M-306.96M
Retained Earnings % of Revenue i--136.3%
Property, Plant & Equipment i77.75M29.38M

Cash Flow Statement Comparison

MetricCATX (2025)AXGN (2025)
Operating Cash Flow i-92.65M10.26M
Operating Cash Flow % of Revenue i-4.6%
Capital Expenditures i-12.75M-3.75M
Free Cash Flow i-95.23M-4.78M
FCF Margin i--2.1%
Debt Repayment i-52,000-32,000
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricCATXAXGN
Shares Short i13.67M3.50M
Short Ratio i9.724.04
Short % of Float i14.32%6.92%
Shares Outstanding i74.34M47.20M
Float Shares i74.26M50.75M
% Held by Insiders i10.82%2.12%
% Held by Institutions i54.41%88.11%
% Held by Public i34.77%9.77%

Dividend Analysis & Yield Comparison: Perspective Therapeutics Inc. vs Axogen Inc.

MetricCATXAXGN
Last 12-Month Dividend iN/A$0.00
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/A$0.00
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/A$0.00
Ex-Dividend DateN/AN/A